Tibotec
 | |
| Industry | Pharmaceutical |
|---|---|
| Founded | 1994 |
| Founders |
|
| Defunct | 2002 |
| Fate | Acquired by Johnson & Johnson and merged into its Janssen Pharmaceuticals division |
| Website | tibotec |
Tibotec was a pharmaceutical company with a focus on research and development of the treatment of infectious diseases such as HIV/AIDS and hepatitis C. The company was founded in 1994 and then acquired by Johnson & Johnson and merged into its Janssen Pharmaceuticals division in 2002.
The name of the company is derived from the tetrahydro-imidazo[4,5,1-jk][1,4]-benzodiazepine-2(1H)-one and -thione (TIBO) compounds discovered at the Rega Institute for Medical Research (Belgium).[1]
History
[edit]In 1994, Rudi Pauwels of the Rega Institute for Medical Research founded Tibotec, together with his wife Carine Claeys, and their first co-workers Marie-Pierre de Béthune, Kurt Hertogs, and Hilde Azijn. In 1995 Paul Stoffels joined Tibotec. The company was acquired by Johnson & Johnson in April 2002,[2] and was renamed Janssen Therapeutics in June 2011.[3]
Tibotec provided funding for HIV treatment clinical trials at the Infectious Diseases Institute in Kampala, Uganda.[4][5]
Drugs
[edit]- Darunavir (TMC114, tradename Prezista), a protease inhibitor
- Etravirine (TMC125, tradename Intelence), a non-nucleoside reverse transcriptase inhibitor (NNRTI)
- Bedaquiline (TMC207/R207910, tradename Sirturo), an diarylquinoline anti-tuberculosis drug[6]
- Rilpivirine (TMC278, tradename Edurant), an NNRTI
- Simeprevir (TMC435, tradename Olysio), an HCV NS3/4A protease inhibitor for treatment of chronic hepatitis C in combination with pegylated interferon/ribavirin or with other direct-acting anti-HCV agents.[7]
- Dapivirine (TMC120), an NNRTI licensed to the International Partnership for Microbicides for its development as a vaginal microbicide in March 2004.
See also
[edit]References
[edit]- ^ Pauwels, Rudi; Andries, Koen; Desmyter, Jan; Schols, Dominique; Kukla, Michael J.; Breslin, Henry J.; Raeymaeckers, Alfons; Gelder, Jozef Van; Woestenborghs, Robert; Heykants, Jozef; Schellekens, Karel; Janssen, Marcel A. C.; Clercq, Erik De; Janssen, Paul A. J. (1990). "Potent and selective inhibition of HIV-1 replication in vitro by a novel series of TIBO derivatives". Nature. 343 (6257): 470–474. Bibcode:1990Natur.343..470P. doi:10.1038/343470a0. PMID 1689015. S2CID 4354080.
- ^ "Johnson & Johnson to Acquire Tibotec-Virco". Johnson & Johnson. 2002-03-22. Archived from the original on 2002-06-08. Retrieved 2023-05-16.
{{cite web}}: CS1 maint: unfit URL (link) - ^ Van Houten, Pamela (2011-06-22). "Tibotec Therapeutics Becomes Janssen Therapeutics, Part Of The Janssen Pharmaceutical Companies". Johnson & Johnson. Archived from the original on 2023-05-17. Retrieved 2023-05-17.
- ^ Schmickle, Sharon (2008-11-13). "University of Minnesota doctors battle AIDS in Uganda". MinnPost. Archived from the original on 2010-06-23. Retrieved 2023-05-16.
{{cite web}}: CS1 maint: unfit URL (link) - ^ "Clinical Research at the Infectious Diseases Institute" (PDF). The Global Health Network. Infectious Diseases Institute. Archived (PDF) from the original on 2023-05-17. Retrieved 2023-05-17.
- ^ Andries, K.; Verhasselt, P; Guillemont, J; Göhlmann, H. W.; Neefs, J. M.; Winkler, H; Van Gestel, J; Timmerman, P; Zhu, M; Lee, E; Williams, P; De Chaffoy, D; Huitric, E; Hoffner, S; Cambau, E; Truffot-Pernot, C; Lounis, N; Jarlier, V (2005). "A Diarylquinoline Drug Active on the ATP Synthase of Mycobacterium tuberculosis". Science. 307 (5707): 223–7. Bibcode:2005Sci...307..223A. doi:10.1126/science.1106753. PMID 15591164. S2CID 33219841.
- ^ Zeuzem S, Berg T, Gane E, et al. (2012). TMC435 in HCV Genotype 1 Patients Who Have Failed Previous Pegylated Interferon/Ribavirin Treatment: Final SVR24 Results of the ASPIRE Trial. 47th Annual Meeting of the European Association for the Study of the Liver. Barcelona, April 18–22, 2012. Abstract 2.